Memorial Sloan-Kettering’s colorectal cancer team has developed online prediction tools that assess disease risk following surgery, enabling patients and physicians to make better treatment decisions.
With the genomics revolution, scientists and physicians have increasingly been able to peer at the inner workings of tumor cells and pinpoint the specific genetic changes that transform them from their cells of origin into cancer.
Dr. Saltz, an internationally recognized expert in developing new drug therapies for colorectal cancer, joined the Memorial-Sloan Kettering faculty in 1989.
For the first time, a new study has shown that removing polyps by colonoscopy not only prevents colorectal cancer from developing, but also prevents deaths from the disease.
Minority patients have a significantly decreased survival from colon cancer compared to white patients, most often as a result of a late diagnosis. To help address this problem, a team of healthcare professionals at Memorial Sloan-Kettering Cancer Center has identified an efficient way to increase minority access to lifesaving colorectal cancer screening (CRCS) in communities where multiple barriers to preventive care exist.
A new study shows that a large majority of patients who present with advanced colorectal cancer that has spread to other organs (stage IV) don’t require immediate surgery to remove the primary tumor in the colon.
New findings from a Decision Analysis for the US Preventative Services Task Force (USPSTF) suggest that routine colorectal cancer screenings can be stopped in patients over the age of 75.